- Home
- ORIC vs LEU Comparison
ORIC vs LEU Comparison
Compare ORIC & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- LEU
- Stock Information
- Founded
- ORIC 2014
- LEU 1998
- Country
- ORIC United States
- LEU United States
- Employees
- ORIC N/A
- LEU N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- ORIC Health Care
- LEU Industrials
- Exchange
- ORIC Nasdaq
- LEU Nasdaq
- Market Cap
- ORIC 974.1M
- LEU 4.2B
- IPO Year
- ORIC 2020
- LEU 1998
- Fundamental
- Price
- ORIC $10.71
- LEU $243.46
- Analyst Decision
- ORIC Strong Buy
- LEU Buy
- Analyst Count
- ORIC 10
- LEU 11
- Target Price
- ORIC $17.33
- LEU $194.80
- AVG Volume (30 Days)
- ORIC 886.3K
- LEU 1.2M
- Earning Date
- ORIC 11-11-2025
- LEU 10-27-2025
- Dividend Yield
- ORIC N/A
- LEU N/A
- EPS Growth
- ORIC N/A
- LEU 10.12
- EPS
- ORIC N/A
- LEU 6.16
- Revenue
- ORIC N/A
- LEU $436,900,000.00
- Revenue This Year
- ORIC N/A
- LEU $3.52
- Revenue Next Year
- ORIC N/A
- LEU $8.01
- P/E Ratio
- ORIC N/A
- LEU $39.53
- Revenue Growth
- ORIC N/A
- LEU 12.72
- 52 Week Low
- ORIC $3.90
- LEU $39.12
- 52 Week High
- ORIC $14.67
- LEU $264.90
- Technical
- Relative Strength Index (RSI)
- ORIC 55.85
- LEU 67.76
- Support Level
- ORIC $10.36
- LEU $214.00
- Resistance Level
- ORIC $11.20
- LEU $232.67
- Average True Range (ATR)
- ORIC 0.49
- LEU 14.74
- MACD
- ORIC 0.06
- LEU 4.45
- Stochastic Oscillator
- ORIC 67.35
- LEU 99.41
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.